Role of anti-angiogenesis therapy in the management of hepatocellular carcinoma: The jury is still out

Table 1 Clinical studies on anti-angiogenesis therapy of hepatocellular carcinoma included in this review

Ref.	Year	Phase	Investigational drug	Outcome
Llovet et al[10]	2008	Phase 3	Sorafenib	Increased survival
Cheng et al[12]	2009	Phase 3	Sorafenib	Increased survival
Lencioni et al[13]	2012	Phase 4	Sorafenib	High safety
Lencioni et al[14]	2014	Phase 4	Sorafenib	High safety
Johnson et al[40]	2013	Phase 3	Brivanib	Less well-tolerated
Cheng et al[41]	2013	Phase 3	Sunitinib	Significantly inferior than sorafenib
Zhu et al[42]	2012	Phase 3	Sorafenib plus erlotinib	No survival benefit
Llovet et al[43]	2013	Phase 3	Brivanib after sorafenib failed	No survival benefit
Zhu et al[44]	2014	Phase 3	Everolimus after sorafenib failed	No survival benefit